Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833537 | 0.82 | LMNA (0.48) | NPC1RAB9AALDH1A1MAPK1KDM4E | |
| SCHEMBL4491073 | 0.82 | ADRB1 (0.48) | ALDH1A1KDM4EDRD2DRD3TP53 | |
| SCHEMBL28583221 | 0.80 | CHRNB2 (0.38) | GFERNPC1RAB9AALDH1A1TSHR | |
| SCHEMBL7189439 | 0.78 | HDAC8 (0.34) | KDM4EMAPTDAODRD2DRD4 | |
| SCHEMBL28935502 | 0.76 | CHRNA7 (0.52) | GFERNPC1RAB9AALDH1A1KDM4E | |
| Indole SCHEMBL28870343 | 0.74 | AHR (0.61) | NPC1ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL2296512 | 0.71 | BPTF (0.31) | DAO | |
| SCHEMBL8309804 | 0.70 | — | — | |
| SCHEMBL9234686 | 0.70 | MAPT (0.46) | GFERNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL28807259 | 0.69 | MAPT (0.49) | GFERNPC1RAB9AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | claimed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | claimed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | claimed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | claimed |
| WO-2011156626-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-15 | — | — | WO | claimed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | claimed |
| WO-2000032598-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC. (US) | 2000-06-08 | — | — | WO | claimed |
| CN-120192314-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-117946111-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-108164381-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20040033977-A1 | Oligonucleotide modulation of cell adhesion | ISIS PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| US-20040033978-A1 | Compositions and methods for treatment of Hepatitis C virus-associated diseases | ISIS PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| US-20040023917-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000032598-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0949261-A1 | SUBSTITUTED PIPERIDINEDIONE DERIVATIVES AND HERBICIDES | NIPPON SODA CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | GFER 922/4885NPC1 1513/4885RAB9A 164/4885 |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | GFER 1142/4885NPC1 1525/4885RAB9A 419/4885 |
| US-20040023917-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | CD2BP2, MICA, CD74 | GFER 3834/4885NPC1 4583/4885RAB9A 4282/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | GFER 4261/4885NPC1 2904/4885RAB9A 3526/4885 |
| US-20040033977-A1 | Oligonucleotide modulation of cell adhesion | VCAM1, ICAM1, EPCAM | GFER 1984/4885NPC1 3399/4885RAB9A 4662/4885 |
| US-20040033978-A1 | Compositions and methods for treatment of Hepatitis C virus-associated diseases | RNASE1, NSUN2, POLRMT | GFER 3089/4885NPC1 1219/4885RAB9A 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.